Retinal Vein Occlusion - Which Treatment When?;Retinaler Venenverschluss - wann, womit und wie therapieren?

Klinische Monatsblatter fur Augenheilkunde

Volumn 234, Issue 10, 2017, Pages 1259-1265

  Bajor, A ^a   Pielen, A ^a   Danzmann, L ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

anti VEGF; BRVO; CRVO; macular edema; retinal vein occlusion

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ALTERNATIVE MEDICINE; ARTICLE; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; IRIS RUBEOSIS; LASER COAGULATION; MACULAR EDEMA; PROGNOSIS; RETINA ISCHEMIA; RETINA VEIN OCCLUSION; SECONDARY GLAUCOMA; SIDE EFFECT; TREATMENT PLANNING; VISUAL ACUITY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY;

ANGIOGENESIS INHIBITORS; DRUG IMPLANTS; HUMANS; INTRAVITREAL INJECTIONS; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85017131508     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0042-123834     Document Type: Article

References (49)

1. Feltgen N. Pielen A. [Retinal vein occlusion: Epidemiology, classification and clinical findings]. Ophthalmologe: 2015; 112 607 618
2. Feltgen N. Pielen A. [Retinal vein occlusion: Therapy of retinal vein occlusion]. Ophthalmologe: 2015; 112 695 704
3. Hayreh S. S. Podhajsky P. A. Zimmerman M. B. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology: 2011; 118 119 133.e2
4. Feltgen N. Pielen A. Hansen Let al. [Intravitreal drug therapy for retinal vein occlusion - pathophysiological mechanisms and routinely used drugs]. Klin Monatsbl Augenheilkd: 2010; 227 681 693
5. Lang G. Lang S. Diagnostik und Therapie retinaler Venenverschlüsse. Klin Monatsbl Augenheilkd: 2010; 227 R141 R155
6. Bertelsen M. Linneberg A. Christoffersen N. et al. Mortality in patients with central retinal vein occlusion. Ophthalmology: 2014; 121 637 642
7. Werther W. Chu L. Holekamp N. et al. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol: 2011; 129 326 331
8. Pielen A. Feltgen N. Isserstedt C. et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PloS One: 2013; 8 e78538
9. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss.: 2010; 227 542 556
10. Coscas G. Loewenstein A. Augustin A. et al. Management of retinal vein occlusion - consensus document. Ophthalmologica: 2011; 226 4 28
11. Berger A. R. Cruess A. F. Altomare F. et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica: 2015; 234 6 25
12. Haller J. A. Bandello F. Belfort R. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology: 2011; 118 2453 2460
13. Mayer W. Hadjigoli A. Wolf A. et al. Vergleich von intravitrealem Dexamethason-Implantat mit intravitrealem Ranibizumab als Erstbehandlung des Makulaödems bei retinalen venösen Gefäβverschlüssen. Klin Monatsbl Augenheilkd: 2015; 232 1289 1296
14. Huang P. Niu W. Ni Z. et al. A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PloS One: 2013; 8 e82454
15. Mitry D. Bunce C. Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev: 2013; 01 CD009510
16. Braithwaite T. Nanji A. A. Lindsley K. et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev: 2014; 05 CD007325
17. Hattenbach L-O. Efficacy and safety of 0.5 mg Ranibizumab compared with 0.7 mg dexamethasone intravitreal implant in patients with branch retinal vein occlusion over 6 months: The COMRADE-B study. Invest Ophthalmol Vis Sci: 2014; 55 1830
18. Hoerauf H. Feltgen N. Weiss C. et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): A European label study. Am J Ophthalmol: 2016; 169 258 267
19. Meyer C. H. Holz F. G. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond): 2011; 25 661 672
20. Xu L. Lu T. Tuomi L. et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci: 2013; 54 1616 1624
21. Ferrara N. Damico L. Shams N. et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina: 2006; 26 859 870
22. Holash J. Davis S. Papadopoulos N. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A: 2002; 99 11393 11398
23. Brown D. M. Heier J. S. Clark W. L. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol: 2013; 155 429 437.e7
24. Papadopoulos N. Martin J. Ruan Q. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis: 2012; 15 171 185
25. Avery R. L. Castellarin A. A. Steinle N. C. et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol: 2014; 98 1636 1641
26. Campochiaro P. A. Brown D. M. Awh C. C. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology: 2011; 118 2041 2049
27. Campochiaro P. A. Sophie R. Pearlman J. et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab. Ophthalmology: 2014; 121 209 219
28. Wecker T. Ehlken C. Bühler A. et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol: 2016; 10.1136/bjophthalmol-2016-308668
29. Chin-Yee D. Eck T. Fowler S. et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol: 2015; 10.1136/bjophthalmol-2015-306987
30. Rayess N. Houston S. KS. Gupta O. P. et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol: 2015; 159 3 8.e1
31. Campochiaro P. A. Wykoff C. C. Singer M. et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology: 2014; 121 2432 2442
32. Clark W. L. Boyer D. S. Heier J. S. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology: 2016; 123 330 336
33. Larsen M. Waldstein S. M. Boscia F. et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL Study. Ophthalmology: 2016; 123 1101 1111
34. Pielen A. Mirshahi A. Feltgen N. et al. Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol: 2015; 93 e29 e37
35. Wang K. Wang Y. Gao L. et al. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull: 2008; 31 1541 1546
36. McAllister I. L. Vijayasekaran S. Chen S. D. et al. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol: 2009; 147 838 846
37. Kunikata H. Shimura M. Nakazawa T. et al. Chemokines in aqueous humour before and after intravitreal triamcinolone acetonide in eyes with macular oedema associated with branch retinal vein occlusion. Acta Ophthalmol: 2012; 90 162 167
38. Ip M. S. Scott I. U. VanVeldhuisen P. C. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol: 2009; 127 1101 1114
39. Scott I. U. Ip M. S. VanVeldhuisen P. C. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol: 2009; 127 1115 1128
40. Haller J. A. Bandello F. Belfort R. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology: 2010; 117 1134 1146.e3
41. Jain N. Stinnett S. S. Jaffe G. J. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology: 2012; 119 132 137
42. Jeanneteau F. Garabedian M. J. Chao M. V. Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci U S A: 2008; 105 4862 4867
43. Augustin A. J. Holz F. G. Haritoglou C. et al. Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica: 2015; 233 18 26
44. Schmitz K. Maier M. Clemens C. R. et al. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. Ophthalmologe: 2014; 111 44 52
45. [Anonymous] Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol: 1986; 104 34 41
46. [Anonymous] A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology: 1995; 102 1434 1444
47. Tomomatsu Y. Tomomatsu T. Takamura Y. et al. Comparative study of combined bevacizumab/targeted photocoagulation vs. bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmol: 2016; 94 e225 e230
48. Rehak M. Tilgner E. Franke A. et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol: 2014; 252 745 752
49. Campochiaro P. A. Hafiz G. Mir T. A. et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE Trial. Ophthalmology: 2015; 122 1426 1437